Published in Cancer Weekly, August 10th, 2004
This trial, referred to as VITAL-1, is based on the promising findings from two previously conducted phase II trials of the vaccine in over 100 patients with advanced prostate cancer. The trial will compare GVAX prostate cancer vaccine to docetaxel (Taxotere) chemotherapy and is expected to enroll approximately 600 patients at more than 50 medical centers across the United States.
In May 2004, Cell Genesys received a Special Protocol...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.